Research ArticleAging

The matricellular protein TSP1 promotes human and mouse endothelial cell senescence through CD47 and Nox1

See allHide authors and affiliations

Sci. Signal.  17 Oct 2017:
Vol. 10, Issue 501, eaaj1784
DOI: 10.1126/scisignal.aaj1784

Keeping endothelial cells young

Aging causes once-proliferating cells to undergo cell cycle arrest and become senescent, thus impairing tissue and organ function. Meijles et al. delineated a pathway that induced senescence in mouse and human endothelial cells. Binding of the matricellular protein TSP1 to its receptor CD47 activated the enzyme Nox1, which generates reactive oxygen species. The subsequent oxidative stress triggered a p53-dependent DNA damage response pathway that resulted in cell cycle arrest. These results suggest that targeting TSP1, CD47, or Nox1 could delay or reverse cellular senescence in the endothelium, which could help improve the quality of life for the growing aging population.


Senescent cells withdraw from the cell cycle and do not proliferate. The prevalence of senescent compared to normally functioning parenchymal cells increases with age, impairing tissue and organ homeostasis. A contentious principle governing this process has been the redox theory of aging. We linked matricellular protein thrombospondin 1 (TSP1) and its receptor CD47 to the activation of NADPH oxidase 1 (Nox1), but not of the other closely related Nox isoforms, and associated oxidative stress, and to senescence in human cells and aged tissue. In human endothelial cells, TSP1 promoted senescence and attenuated cell cycle progression and proliferation. At the molecular level, TSP1 increased Nox1-dependent generation of reactive oxygen species (ROS), leading to the increased abundance of the transcription factor p53. p53 mediated a DNA damage response that led to senescence through Rb and p21cip, both of which inhibit cell cycle progression. Nox1 inhibition blocked the ability of TSP1 to increase p53 nuclear localization and p21cip abundance and its ability to promote senescence. Mice lacking TSP1 showed decreases in ROS production, p21cip expression, p53 activity, and aging-induced senescence. Conversely, lung tissue from aging humans displayed increases in the abundance of vascular TSP1, Nox1, p53, and p21cip. Finally, genetic ablation or pharmacological blockade of Nox1 in human endothelial cells attenuated TSP1-mediated ROS generation, restored cell cycle progression, and protected against senescence. Together, our results provide insights into the functional interplay between TSP1 and Nox1 in the regulation of endothelial senescence and suggest potential targets for controlling the aging process at the molecular level.


Aging represents a major global health challenge because improvements in disease management prolong life but often at a substantial financial burden (1). Strikingly, worldwide life span elongation and disease comorbidities are strongly associated, a pattern typified in cardiopulmonary-vascular diseases (2). However, specific targeted therapies combating vascular decline in the aging process are absent despite viable regimens to manage vascular diseases (3). Therefore, new mechanistic challenges exist as a consequence of the aging process and an overall decline in holistic health. It is logical, therefore, that attacking the seminal cause of aging rather than individual disease processes will promote greater improvements in life span and quality of life (4).

Cellular senescence is recognized as a central hallmark of the aging process, which occurs when cells withdraw from the cell cycle and lose the capacity to proliferate in response to growth factors or mitogens (5, 6). Moreover, senescent vascular cells are observed in human atherosclerotic plaques and hypertensive samples (7, 8). Senescence is an irreversible form of cell cycle arrest initiated by various stresses including genotoxic and oxidative stress (9), leading to DNA damage, oncogene activation, and telomere shortening (10). Although senescent cells remain minimally functional and metabolically active, they cannot undergo mitosis, and augmented senescence is deleterious to organ function vis-à-vis interference with tissue self-renewal.

In addition to cell cycle arrest, senescent cells accumulate senescence markers, including senescence-associated β-galactosidase (SA-β-Gal), and secrete vasoactive factors (11). Matricellular thrombospondins were initially characterized as a highly abundant family of proteins in Werner syndrome fibroblasts, which have a severely curtailed replicative life span (12). Thrombospondin 1 (TSP1) abundance is inversely correlated with proliferation in some cell types (13). However, insight into TSP1-suppressed proliferation remains unknown.

As reported by Harman (14), oxidative stress has been considered a key driver of the aging process, and subsequent studies have inferred a link between oxidative stress and senescence. Of the highly conserved family of NADPH (reduced form of nicotinamide adenine dinucleotide phosphate) oxidase (Nox) isozymes, which produce reactive oxygen species (ROS), two isoforms are generally considered as promitotic and are pivotal to several pathologies involving hyperproliferation. Accordingly, interest in Nox inhibitor development has intensified and therefore represents an opportunity to interrogate, with therapeutic translation, the link between ROS and aging (15). Here, we present data suggesting a causal role of TSP1-induced increase in the abundance of Nox1 (but not the closely related Nox2, Nox4, or Nox5) in cellular senescence across a wide range of ages in humans, thus challenging the dogma of a primarily pro-proliferative and proapoptotic role for Nox1. We provide mechanistic insight into senescence triggered by p53-p21cip-Rb, and not p16INK4A, in human cells and mouse models. We validated our discovery with genetic and pharmacological tools in tissues of humans of increasing age, in mice lacking TSP1 or Nox1, in human endothelial cells challenged with TSP1, and in endothelial cells overexpressing Nox1. Finally, our studies offer an exciting new therapeutic translation of a selective Nox1 inhibitor as a modality to target senescence-associated endothelial dysfunction.


TSP1 is increased in human aging and induces endothelial senescence

Age-related diseases are associated with increased matrix remodeling and matricellular protein abundance (12, 1619). Of these matricellular proteins, TSP1 is intriguing because of its reported association with age-related pulmonary diseases including pulmonary hypertension, chronic obstructive pulmonary disease, and idiopathic pulmonary fibrosis (2024). To explore the functional role of TSP1 in aging and disease, we examined whether TSP1 associated with human pulmonary aging by analyzing disease-free lung biopsies (table S1). We observed a strong positive relationship between TSP1 mRNA and increasing age (Fig. 1A), as is suggested by aging muscle data housed at the NCBI (National Center for Biotechnology Information) database (accession #GDS156). Next, we investigated TSP1 localization in pulmonary arteries obtained by rapid autopsy of non–pulmonary-diseased subjects (table S2). Consistently, we observed notable differences in TSP1 immunofluorescence across the vessel wall (Fig. 1B), with a significant increase in intimal TSP1 immunofluorescence in arteries from aged subjects compared to younger controls (Fig. 1C and fig. S1A).

Fig. 1 TSP1 is increased in aging human lung vasculature and induces endothelial cell cycle arrest in vitro.

Data for human tissue are shown in green; data for cell experiments are shown in red; data in gray are the corresponding controls. (A) Correlation of TSP1 expression as quantified by quantitative reverse transcription polymerase chain reaction (qRT-PCR) with age in human lung homogenates (n = 7 subjects; r2=0.69, P = 0.02). Data points are means of three replicates of the same sample. (B) Representative images of TSP1 protein abundance in the intimal and medial layer of human pulmonary arteries of a 73-year-old subject (right; arrows indicate intima) compared to an artery from a 36-year-old subject (left) as determined by immunofluorescence (IF). Scale bar, 100 μm. L, vascular lumen. (C) Quantitation of immunofluorescence images from six subjects (n = 4 samples each, 10 to 20 images per sample) is plotted as a linear regression; equation, r2, and P values are as indicated. MFI, mean fluorescence intensity. (D) Cell cycle profile analysis of vehicle (left) and TSP1-challenged (right) HPAECs measured by propidium iodide (PI) labeling and fluorescence-activated cell sorting (FACS). FL-2, fluorescence channel 2. (E) Quantitative analysis of cell cycle phase distribution of HPAECs. Data are the means ± SEM of 20,000 events (n = 4 biological replicates per treatment group) expressed as percentage. *P < 0.05 for TSP1 challenge compared to vehicle control by Mann-Whitney test of each phase. (F and G) HPAEC proliferation in the presence or absence of TSP1, as measured by trypan blue exclusion assay (F) and MTT assay (G). Data are means ± SEM (n = 3 biological replicates per treatment). P < 0.001 for TSP1 compared to vehicle control by repeated-measures analyses. (H) BrdU incorporation in HPAECs in the presence or absence of TSP1 at 24 hours. Data are means ± SEM (n = 3 biological replicates per treatment). *P < 0.05 for TSP1 challenge compared to vehicle control by Student’s t test.

We next explored the functional effects of TSP1 on endothelial cell physiology using primary human pulmonary artery endothelial cells (HPAECs). HPAECs were chosen because they are a well-characterized and readily available model for studying cell-mediated processes in pulmonary disease (25, 26). We found that TSP1 induced cell cycle arrest of HPAECs (Fig. 1D), characterized by increased numbers of cells in G1-G0 and decreased numbers of cells in S and G2-M (Fig. 1E). In line with the ability of TSP1 to block cell proliferation induced by serum, nitric oxide (NO), or fibroblast growth factor 2 (13, 27), TSP1 significantly inhibited HPAEC proliferation, as detected by trypan blue exclusion (Fig. 1F), MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay (Fig. 1G), and 5-bromo-2′-deoxyuridine (BrdU) incorporation (Fig. 1H). This effect was achieved using a TSP1 concentration (2.2 nM) detected in the plasma of diseased patients (28, 29) and was not enhanced by higher concentrations (fig. S1, B and C).

Blunted proliferation and halted cell cycle progression are hallmarks of cellular senescence (6), a phenotypical switch associated with organismal aging and organ dysfunction (30). To ascertain a functional role for TSP1 in proliferative signaling in vivo and corroborate our primary findings in human cells, we assessed middle-aged (8- to 10-month-old) mouse lungs for proliferating cell nuclear antigen (PCNA) (31) in wild-type and TSP1−/− mice (Fig. 2A). Middle-aged mice were chosen because their tissues are terminally differentiated (32), mirroring the early stages of age-related complications in humans (33). Immunoblotting revealed a significant increase in PCNA abundance in TSP1−/− mice compared to age-matched wild-type controls. Accordingly, TSP1 exposure significantly decreased PCNA abundance in HPAECs (Fig. 2B). On the basis of these observations and the increase in expression of self-renewal genes in CD47-null endothelial cells (34), we investigated whether TSP1 drove HPAEC senescence. TSP1 exposure significantly increased the number of SA-β-Gal–positive HPAECs and human aortic endothelial cells (Fig. 2C), which showed concentration dependency (fig. S1D), and elicited an enlarged and flattened cell shape characteristic of senescence (Fig. 2D) (35), supporting a work in brain endothelial cells (36). To assess in vivo relevance of our discoveries, we performed SA-β-Gal staining, which was lower in TSP1−/− mouse lung tissue than in wild-type mouse lung tissue (Fig. 2E). This observation, coupled with similar collagen staining between the two genotypes (Fig. 2E, blue stain, and fig. S1E), precluded collagen-induced vascular senescence (37). Notably, middle-aged wild-type lungs were abundant in senescent markers, with increased p53 and p21cip, decreased Rb, and no change in p16INK4A, compared to younger controls (fig. S2A). Moreover, aging decreased PCNA abundance in wild-type animals. Because the senescent phenotype is not only associated with cell cycle arrest and cell function decline, we sought to ascertain the role of the senescence-associated secretory phenotype (SASP) components in TSP1-mediated senescence. SASP factors include many inflammatory cytokines, growth factors, and proteases, among others (3840). Immunoblotting demonstrated that some SASP factors [monocyte chemoattractant protein-1 (MCP-1) and p19Arf] were lower in abundance in TSP1−/− lung homogenates compared to those from their wild-type counterparts (Fig. 2F). These observations in aging tissues and endothelial cells support TSP1 as an instigator of cellular senescence.

Fig. 2 TSP1 promotes cell and tissue senescence in vitro and oxidative stress in wild-type middle-aged mice.

Data for TSP1−/− samples are plotted in purple; data for cell experiments are in red; data in gray represent the corresponding controls. (A and B) Abundance of the S phase–associated proliferation marker PCNA in middle-aged TSP1−/− mice (purple bar) compared to age-matched wild-type controls (gray bar) as analyzed by Western blotting (A) and in HPAECs exposed to TSP1 as analyzed by immunofluorescence (B). Data are means ± SEM [n = 6 animals per group (A); n = 3 cell populations per treatment, 10 to 20 images per immunodetection (scale bar, 20 μm)] (B); *P < 0.05 compared to wild-type or vehicle control by Student’s t test. (C to F) Endothelial cell senescence as detected by SA-β-Gal labeling [C; HPAECs and human aortic endothelial cells (HuAoECs)] and increases in cell size (D; HPAECs). SA-β-Gal (E, left) and trichrome staining (E, right) were used on en face tissue to visualize senescence, gross lung vessel morphology, and collagen deposition (blue) in middle-aged wild-type and TSP1−/− lungs. The abundance of SASP factors [MCP-1, p19Arf, and interleukin-6 (IL-6)] was assessed by Western blotting in middle-aged TSP1−/− and age-matched wild-type controls (F; purple compared to gray bars). Data are means ± SEM (n = 3 independent experiments or n = 3 animals; 12 images per group). Scale bar, 100 μm. *P < 0.05 for TSP1 challenge compared to vehicle control or null compared to age-matched wild-type mice by Student’s t test. (G and H) NADPH-driven O2•− (G; cytochrome c assay) and H2O2 (H; Amplex Red assay) production in HPAEC lysates. Data are means ± SEM (n = 4 biological replicates per treatment). *P < 0.05 compared to vehicle controls by Student’s t test. (I and J) En face cell-permeant O2•− scavenger (Tiron)–inhibitable dihydroethidium (DHE)–ROS, as measured by fluorescence microscopy (I), and NADPH-driven homogenate O2•− production, as measured by cytochrome c reduction (J). Data are means ± SEM (n = 3 to 6 mice per group). Scale bar, 50 μm. *P < 0.05 compared to wild-type controls by Student’s t test. a.u., arbitrary units.

TSP1 promotes p53-dependent DNA damage response and senescence

The aged pulmonary vascular tree is subject to an imbalance between oxidants and antioxidants and attendant oxidative stress (41), a process associated with the free radical theory of aging (14). Therefore, a link between senescence, oxidative stress, and TSP1 could offer insight into the aging process. In HPAECs exposed to TSP1, O2•− and H2O2 production, both of which are indicators of oxidase activity, were increased (Fig. 2, G and H). Next, we interrogated O2•− production in middle-aged wild-type and TSP1−/− lungs using two complementary assays. TSP1−/− lungs displayed significantly lower O2•− by en face fluorescence (Fig. 2I) and decreased NADPH-driven O2•− measured by the reduction of cytochrome c (Fig. 2J). These findings, together with increased ROS in middle-aged mouse lungs compared to young controls (fig. S2B), suggested a role for TSP1-induced Nox-mediated ROS as a driver of endothelial senescence.

We discovered that TSP1 activated the DNA damage response (DDR) senescence pathway. Rb abundance was reduced, and Ser15 in p53 was phosphorylated in HPAECs exposed to TSP1 compared to vehicle control. p53-independent senescence signaling through p16INK4A (18) was excluded because p16INK4A abundance remained unchanged in response to TSP1 (Fig. 3A) and was not increased in middle-aged wild-type mouse lungs (fig. S2A). This finding distinguished TSP1 from other matricellular proteins such as CCN1, which signals through p16INK4A (18). We observed an increase in total p53 and p21cip in middle-aged mice (fig. S2A). Moreover, we discovered that TSP1 exposure increased p53 abundance in HPAECs in a time-dependent fashion (Fig. 3B) and increased p53 activation, as evidenced by its increased nuclear localization (Fig. 3C). Moreover, TSP1 exposure significantly increased the number of HPAECs positive for p21cip (Fig. 3D), the downstream transcriptional target of p53 activation that encodes a cell cycle–inhibiting factor (42). The increase in the number of SA-β-Gal–positive cells was blocked by p53 silencing, confirming a role for p53 in TSP1-induced endothelial senescence (Fig. 3E and fig. S2C). The abundance of p53 and p21cip was subsequently evaluated in mice. TSP1−/− lungs had significantly lower p21cip mRNA (Fig. 3F) and protein (Fig. 3G) abundance compared to age-matched controls, with the abundance of p53 remaining unchanged (Fig. 3, F and G) but active (phosphorylated) p53 decreasing markedly in nulls (Fig. 3G). Because TSP1−/− tissue exhibited lower amounts of O2•− (Fig. 2, I and J), we reasoned that changes in p21cip abundance resulted from a difference in p53 activation, as evidenced by decreased p53-Ser15 phosphorylation (Fig. 3G) (43, 44). Because p53 evokes apoptotic signaling, we asked whether TSP1 promoted apoptosis of HPAECs (45). However, apoptosis, as measured by trypan blue cell counting (fig. S3A) and sub–G1-G0 FACS quantification (fig. S3B), was unaffected by TSP1 exposure. These observations are consistent with the role of TSP1 in p53-mediated DDR senescence, exclusive of apoptosis.

Fig. 3 TSP1 induces DDR-p53-p21cip–mediated senescence.

Data for TSP1−/− samples are depicted in purple; data for cell experiments are in red; data in gray are the corresponding controls. (A) Abundance of Rb, total and phospho-Ser15 p53, and p16INK4A after 24 hours of TSP1 challenge in HPAECs, as measured by Western blot. Data are means ± SEM (n = 3 biological replicates per treatment); *P < 0.05 compared to vehicle by Student’s t test. (B) Time-dependent changes in p53 abundance in HPAECs stimulated with TSP1, as measured by Western blot. Graphical data are means ± SEM (n = 3 biological replicates per treatment), by repeated-measures analysis. (C and D) Activation of the p53 pathway, as assessed by nuclear localization of p53 (C), and p21cip abundance (D), as measured by immunofluorescence, compared to vehicle controls. Data are means ± SEM (n = 3 biological replicates per treatment; 12 to 20 images per sample). Scale bar, 40 μm. *P < 0.05 for TSP1 challenge compared to vehicle control by Student’s t test. DAPI, 4′,6-diamidino-2-phenylindole. (E) Effect of p53 knockdown by small interfering RNA (siRNA) on TSP1-induced senescence in HPAECs. Graphical data are means ± SEM (n = 3 biological replicates per treatment). Scale bar, 40 μm. *P < 0.05 for TSP1 challenge compared to vehicle control; #P < 0.05 for p53 siRNA-TSP1 compared to scrambled siRNA (SCR)–TSP1 by one-way analysis of variance (ANOVA). (F) mRNA expression of p53 and p21cip in middle-aged TSP1−/− animals. Data are means ± SEM (n = 3 individual animals for each group). *P < 0.05 compared to wild-type by Student’s t test. (G) Abundance of p21cip and total and phospho-p53 in middle-aged TSP1−/− lungs compared to wild-type, age-matched controls. Graphical data are means ± SEM (n = 6 animals per group). *P < 0.05 for TSP1−/−compared to wild-type by Student’s t test.

Aging-linked TSP1-mediated cellular stress is elicited by Nox1

To gain further insight into the mechanisms modulating matricellular-induced cellular O2•− and DDR-senescence pathway activation, we first sought to identify the receptor responsible for these effects of TSP1. TSP1 reportedly binds and activates several cell-surface receptors, three of which are prominent in the endothelium. A blocking antibody against the cognate TSP1 receptor CD47 attenuated TSP1-induced O2•− production in HPAECs (Fig. 4A). Moreover, 7N3, a receptor binding peptide that mimics the C-terminal binding domain of TSP1 (46, 47), significantly increased NADPH-dependent O2•− generation (Fig. 4B). In addition to CD47, the TSP1 receptors signal regulatory protein α (SIRPα) and CD36 are also present in endothelial cells (13, 48, 49). FACS analysis indicated that the abundance of CD47 was similar to that of SIRPα and greater than that of CD36 (fig. S4, A to C). However, antagonizing antibodies against SIRPα and CD36 did not significantly affect O2•− production (Fig. 4C and fig. S4D). Therefore, of the potential culprits, the TSP1-CD47 axis selectively regulated cellular O2•− production.

Fig. 4 TSP1 induces Nox1-dependent O2•− production in HPAECs through its receptor CD47.

Data for TSP1−/− samples are shown in purple; data for cell experiments are shown in red; data in gray are the corresponding controls. (A and B) NADPH-driven O2•− production, as measured by cytochrome c reduction assay in HPAECs exposed to TSP1 in the presence or absence of a specific CD47 blocking antibody (Ab) (A) or the CD47-activating peptide 7N3 (B). Data are means ± SEM (n = 3 biological replicates per treatment). *P < 0.05 for TSP1 challenge compared to vehicle control (veh) by one-way ANOVA and t test, respectively. (C) TSP1-induced O2•− production in HPAECs exposed to a specific SIRPα blocking antibody. Data are means ± SEM (n = 3 biological replicates per treatment). *P < 0.05 for TSP1 challenge compared to vehicle control by one-way ANOVA. (D) TSP1-induced O2•− production in HPAECs exposed to inhibitors of eNOS (L-NAME), mitochondrial complex I [rotenone (Rot)], or xanthine oxidase [oxypurinol (Oxy)]. Data are means ± SEM (n = 3 biological replicates per treatment). *P < 0.05 for TSP1 challenge compared to inhibitor vehicle control; #P < 0.05 for inhibitor compared to TSP1-vehicle by Student’s t test. (E) TSP1-induced O2•− production in HPAECs pretreated with the Nox1- and Nox2-specific inhibitory peptides, NoxA1ds (left) or Nox2ds-tat (right) or their respective scrambled controls (SCRAMB). Data are means ± SEM (n = 3 biological replicates per treatment). *P < 0.05 for TSP1 challenge compared to vehicle by one-way ANOVA. (F to H) Abundance in Nox family members in TSP1-challenged HPAECs, as assessed by Western blotting (F) and FACS (G). Graphical data are means ± SEM (n = 3 biological replicates per treatment). *P < 0.05 for TSP1 challenge compared to vehicle control by Student’s t test. For qRT-PCR analysis (H), *P < 0.05 indicates significance for TSP1 challenge compared to vehicle control by Mann-Whitney test. (I and J) Nox1 abundance in lungs of TSP1−/− mice and wild-type age-matched controls at the mRNA level as demonstrated by RT-PCR (I) and at the protein level as demonstrated by immunoblotting (J). Graphical data are means ± SEM (n = 3 to 6 animals per group). *P < 0.05 for TSP1−/− compared to wild-type control by Student’s t test.

Because TSP1 exposure decreased NO concentrations (fig. S4E), as previously reported (50), we initially postulated that uncoupled endothelial NO synthase (eNOS) could be the major O2•− source. However, O2•− concentrations were not affected by the potent eNOS inhibitor Nω-nitro-l-arginine methyl ester (L-NAME), the mitochondrial inhibitor rotenone, or the xanthine oxidase inhibitor oxypurinol (Fig. 4D). In contrast, diphenyleneiodonium (DPI), a broad-profile flavoprotein inhibitor that targets Nox isoforms, ablated TSP1-induced O2•−. We have previously reported that acute TSP1 exposure activates the Nox1 isoform in smooth muscle (46, 49). We thus used our selective Nox1 inhibitor, NoxA1ds (51), and a specific Nox2 inhibitor, Nox2ds-tat (52, 53). TSP1-induced O2•− production was abolished by the selective Nox1 inhibitor but not by the Nox2-specific inhibitor (Fig. 4E), and the findings with Nox1 were confirmed with siRNA-mediated gene silencing (fig. S4, F and G). Consequently, these results indicated that Nox1 was the major source of TSP1-induced O2•− in endothelial cells and potentially a source of aging-induced ROS.

To investigate a link between endothelial senescence and a TSP1-induced increase in Nox-produced ROS, we examined the effects of TSP1 exposure on the abundance of various Nox subunits. Western blot analysis revealed that only the Nox1 catalytic subunit was significantly increased (Fig. 4F). The Nox2 catalytic subunit and NoxO1, the canonical Nox1 organizing subunit, exhibited a tendency toward increased abundance that was not significant, whereas the abundance of the Nox1 activating subunit NoxA1 or the alternate organizer p47phox was unaffected. FACS (Fig. 4G) and mRNA (Fig. 4H) analysis confirmed that TSP1 exposure significantly increased Nox1 abundance. Nox4 mRNA was significantly increased but to a markedly lower degree and without a corresponding increase in Nox4 protein abundance. Supporting these cellular observations, Nox1 mRNA abundance was lower in the lungs of middle-aged TSP1−/− mice compared to wild-type mice (Fig. 4I). Similarly, we observed that Nox1 protein abundance was significantly lower in middle-aged TSP1−/− lungs compared to controls (Fig. 4J), with the abundance of Nox2 and Nox4 remaining unaffected (fig. S4H). In aggregate, these results suggest that Nox1 is the dominant oxidase mediating TSP1-induced endothelial DDR senescence.

Nox1 is a target in human matrix protein–mediated endothelial senescence

We postulated that increased Nox1 abundance was sufficient to induce HPAEC senescence. Nox1 reportedly displays constitutive activity, generating O2•− because of interactions between the catalytic membrane-spanning Nox1 subunit in association with p22phox and the cytosolic organizing NoxO1 and activator NoxA1 subunits bound through C-terminal interactions with Rac1/2 (54). Consistent with our hypothesis, the number of SA-β-Gal–positive cells was significantly increased in cells transfected with human Nox1 (Fig. 5A) compared to empty plasmid controls. Nox1 overexpression (Nox1OE) was confirmed by FACS analysis (fig. S5A) and mirrored increased O2•− production (Fig. 5B and fig. S5B). Furthermore, middle-aged Nox1-null (Nox1−/−) mice produced significantly less pulmonary NADPH-driven O2•− than wild-type mice (Fig. 5C). Moreover, decreased Nox1-derived O2•− was linked to a significant decrease in p21cip expression without changes in p53 expression (Fig. 5D). These in vivo results were corroborated with Nox1OE cells, which showed increased p21cip abundance and decreased Rb phosphorylation (fig. S5C). To confirm the role of Nox1 as a potential therapeutic strategy in age-related TSP1-induced senescence, we investigated the ability of the selective Nox1 inhibitor NoxA1ds to attenuate the effects of TSP1 in vitro. In both the MTT-based assay (Fig. 5E) and trypan blue assay (Fig. 5F), NoxA1ds reversed the ability of TSP1 to inhibit endothelial cell proliferation. Moreover, NoxA1ds treatment restored normal cell cycle progression in HPAECs exposed to TSP1 (Fig. 5G). In contrast, Nox1OE reduced cell proliferation (fig. S5D) and cell cycle progression (fig. S5E). Consistent with the notion that TSP1-induced senescence was Nox1-mediated, TSP1 promoted increased p53 nuclear localization and p21cip induction in control cells (Fig. 5H, top), effects that were abrogated by Nox1 inhibition (Fig. 5H, bottom). Moreover, NoxA1ds restored PCNA abundance in TSP1-challenged cells (fig. S5F). These findings support a model in which Nox1 orchestrates TSP1-induced endothelial cell senescence through a DDR-dependent mechanism.

Fig. 5 Nox1 as a potential therapeutic target to inhibit matricellular-mediated endothelial senescence.

Data for Nox1OE are shown in blue; data for Nox1−/− samples are shown in orange; data for cell experiments are shown in red; data in gray are the corresponding controls. (A and B) Effect of human Nox1OE on SA-β-Gal staining and O2•− production. Graphical data are means ± SEM (n = 3 biological replicates per treatment). Scale bar, 40 μm. *P < 0.05 for Nox1 plasmid compared to empty plasmid control by Student’s t test. (C) NADPH-driven O2•− production, as measured by cytochrome c reduction assay in middle-aged wild-type and Nox1−/− mouse lungs. Left: Representative cytochrome c kinetic curve. Right: Quantification of O2·− production. Bar graphs are means ± SEM (n = 6 mice per group). *P < 0.05 compared to wild-type by Student’s t test. (D) mRNA expression of p53 and p21cip in wild-type and Nox1−/− mouse lungs. Data are the means ± SEM (n = 3 mice per group); *P < 0.05 compared to wild type by Student’s t test. (E to G) Effect of Nox1 inhibition (using NoxA1ds) on TSP1-induced cell cycle arrest in HPAECs, as measured by MTT assay (E), trypan blue exclusion assay (F), and cell cycle profile analysis (G). Graphical data are means ± SEM (n = 3 to 4 biological replicates per treatment). *P < 0.05 for TSP1 challenge compared to scrambled vehicle control (SCRAMB) by one-way ANOVA. (H) Activation of p53 (red), as assessed by nuclear localization (DAPI-labeled, blue) and p21cip immunofluorescence (green) in HPAECs challenged with TSP1 in the presence or absence of the Nox1 inhibitor NoxA1ds. Graphical data are means ± SEM (n = 3 biological replicates per treatment, 12 to 20 images per group). Scale bar, 50 μm. *P < 0.05 for TSP1 challenge compared to scrambled vehicle control by one-way ANOVA.

Translational relevance of our in vitro and in vivo findings was further assessed in human lung biopsies from disease-free subjects and mice of varying ages. We detected a strong correlation between the rates of generation of O2•− (Fig. 6A) and its metabolite H2O2 (Fig. 6B) in human lung homogenate with advancing age. We also addressed whether Nox1 abundance was increased with advancing human age because of growing evidence for a role for Nox1 in promoting myriad pathologies (5559). We showed a significant correlation between increasing age and the abundance of Nox1 protein (Fig. 6C) and a trend toward an increase in mRNA (fig. S6A) in humans. No significant change in protein was observed with other vascular isoforms (Nox2, Nox4, or Nox5; fig. S6, B to E). An increase in Nox1 abundance but not that of Nox2 or Nox4 was also corroborated in middle-aged mouse lungs compared to young controls (fig. S6F). Accordingly, human aging correlated significantly with the abundance of p53 and p21cip (Fig. 6D). Further supporting the potential clinical relevance of our findings, we discovered that Nox1 localized predominantly in the intima of human pulmonary arteries (Fig. 6E, top) and was significantly increased in samples from older subjects compared to those from younger subjects. Similarly, confocal visualization identified increased p21cip with human age in the intimal endothelium (Fig. 6E, bottom), consistent with the clinical translation potential of this pathway. Finally, we confirmed that Nox1 mediated the senescence phenotype in response to TSP1 because NoxA1ds attenuated TSP1-induced senescence in HPAECs (Fig. 6F). Together, these results highlight a role for Nox1 in aging-associated endothelial p53-mediated activation of the DDR pathway and in driving a prosenescent phenotype. Furthermore, agents targeting Nox1 hold promise for slowing or averting this cell fate.

Fig. 6 Potential clinical relevance of Nox1-mediated endothelial senescence in human pulmonary vascular tissue.

Data points for human tissue are shown in green; data for cell experiments are shown in red; data in gray are the corresponding controls. Data for (A) to (E) are plotted as linear regression (n = 8 samples); equation, r2, and P values are indicated in the corresponding graph. (A and B) Correlation between NADPH-driven O2·− production, as measured by cytochrome c reduction (A), or H2O2 production, as measured by Amplex Red fluorescence (B), and age in human lung homogenates. (C and D) Abundance of Nox1 (C) and p53 and p21cip (D), as measured by Western blot of total homogenates of aging human lung. (E) Intimal immunofluorescence for Nox1 (top, green) and p21cip (bottom, red) in aged human lung sections. Scale bar, 50 μm. Graphs show linear regression analyses. (F) HPAEC senescence induced by TSP1 in the presence or absence of NoxA1ds, as measured by SA-β-Gal staining. Graphical data are means ± SEM (n = 3 biological replicates per treatment). Scale bar, 40 μm. *P < 0.05 for TSP1 challenge compared to scrambled vehicle control by Student’s t test.


Cell senescence is a major hallmark and underpinning of age and premature death. Undoubtedly, over the past two centuries, mankind has seen major improvements in life span, largely as a result of treatment of targeted organ dysfunction and disease. Now, however, there is reasonable concern that extant drug regimens have become so effective that new strategies will yield incremental or, in combination, deleterious effects. Thus, a more fundamental and mechanistic inquiry into the root cause of organismal decline might be expected to yield substantively greater gains in the length and quality of life. With an aging global population, a better understanding of the fundamental mechanisms underlying age-related senescence is of paramount importance (60). We proffer that the study of the actions of matricellular proteins in aging could advance our knowledge of this process. Matricellular proteins increase with age (61), but a causal, rather than a circumstantial, relationship has not been investigated to date.

Associations between increasing age and cardiovascular complications are particularly striking (2, 62, 63). Thus, improved mechanistic insight and identification of molecular targets in age-related vascular disease are critical. Cellular senescence, occurring when cells withdraw from the cell cycle and lose the capacity to proliferate in response to growth factors or mitogens (6), was first described in rapidly replicating human fibroblasts. Senescence is an irreversible form of cell cycle arrest initiated by various stresses, including genotoxic and oxidative stress (9), leading to DNA damage, oncogene activation, and telomere shortening (10). However, endothelial cell senescence may be considered protective in its ability to stave off vascularization and, in turn, blunt tumor growth (64). On balance, however, augmented senescence with age is deleterious to organ function vis-à-vis interference with tissue self-renewal. Here, we discovered that the matricellular protein TSP1 played a role in human endothelial senescence by increasing the abundance and activation of the Nox1 isozyme. In turn, Nox1-dependent ROS led to p53-p21cip-Rb DDR pathway activation and endothelial cell senescence (Fig. 7). This pathway was interrogated using (i) human clinical biopsies and pulmonary artery samples, (ii) genetically modified middle-aged mice lacking TSP1 or Nox1, (iii) primary human endothelial cells, and (iv) human Nox1-overexpressing endothelial cells. Supporting the impact of our findings, translational application was demonstrated using a selective Nox1 inhibitor in human cells.

Fig. 7 A signaling model for TSP1-induced senescence.

Upon binding to CD47, TSP1 activates the Nox1 complex, which generates robust and sustained accumulation of ROS. In turn, this triggers committed senescence through a pathway involving p53-p21cip–induced DNA damage response and decreased Rb phosphorylation. This pathway can be disrupted using the selective Nox1 inhibitor NoxA1ds.

Findings of increased TSP1 abundance in aged mouse cardiac tissue (65) sparked our interest into the role of TSP1 in the decline of cellular and organ function in the aging process. Here, we discovered a link between age and TSP1 abundance in human lung biopsies, which aligns mechanistically with TSP1-induced human endothelial cell cycle arrest and decreased proliferation corroborated by three independent methods (Fig. 1). These data were supported by a mouse model of aging in vivo, in which deletion of TSP1 resulted in increased PCNA abundance. Moreover, in human endothelial cells, TSP1 decreased PCNA abundance and enhanced senescence, as distinguished by β-Gal staining and cell morphology (Fig. 2). Tissues from TSP1−/− mice showed decreased senescence compared to those from age-matched wild-type mice. Together, our current findings identified a role for TSP1 in endothelial senescence, which involves cell cycle progression inhibition, oxidative stress, and p53-mediated DDR signaling.

Organ homeostasis is perturbed upon the accumulation of somatic senescent cells in tissues (5, 6). Hence, senescence is considered an inexorable cell fate in mammals and other organisms (30, 66) and represents a maladaptive response leading to dysfunction and vascular disease. One suggested determinant of in vivo senescence at the molecular level corresponds to the accumulation of oxidative damage triggered by a chronic mild increase in ROS (9). These ROS (for example, O2•− and its more stable and cell-permeant H2O2 product) can impair normal cellular processes by oxidizing macromolecules and damaging organelles (67) and have been associated with disease progression (41). Our data align with the free radical theory of aging in two ways. We discovered a key relationship between age, Nox1, and human lung ROS (Fig. 6). Second, our findings support matricellular TSP1 inducing human endothelial cell ROS and senescence, along with an exhibited suppression of O2•− production in TSP1−/− mouse lungs (Fig. 2). Our findings, combined with reduced senescence and SASP factors in these knockout animals, underscore a functional link between TSP1, Nox1, and senescence.

Of the macromolecules altered by ROS, dysfunctional oxidized DNA repair commits cells to senescence through activation of the DDR pathway, a phenomenon that has been observed in various forms of cancer, neurodegenerative disorders, and infertility (68, 69). A common ancestral feature shared in DDR senescence is the effector p53 (67), which, after Ser15 phosphorylation, facilitates S-phase transition blockade through transcriptional regulation of p21cip (44). In cultured HPAECs, we observed a time-dependent increase in p53 abundance and activation (as visualized by nuclear localization) and reversal of TSP1-induced senescence by p53 knockdown (Fig. 3). We ruled out apoptosis in this response by trypan blue exclusion and FACS (fig. S3). These findings were corroborated in middle-aged mice by demonstrating that TSP1 deficiency suppressed the abundance of p21cip but not that of p53 (Fig. 3). In human biopsies, we observed a correlation between TSP1 induction of p53-mediated senescence and increasing age (Fig. 6).

Senescence relies on two main molecular pathways: p16INK4A-Rb and p53-p21cip-Rb signaling. Both pathways converge at the level of Rb, and hypophosphorylated Rb with p53 indicates committed senescence (42). TSP1 promoted p53-p21cip-Rb–dependent senescence independently of p16INK4A-Rb. These findings contrast with the effects of CCN1, another matricellular protein that promotes both p53- and p16INK4A-dependent fibroblast senescence (18), and may suggest a greater role for TSP1 in committed senescence. However, these disparate signaling effects could be cell- and context-dependent and perhaps hinge on the components in a specific milieu of other pro-proliferative and senescence factors. Moreover, given that p53 increases the intracellular abundance of TSP1, which stabilizes p53 tumor suppressor activity (20), it is tempting to speculate that a vicious cycle of TSP1-Nox1-p53 signaling is set in motion. Further studies are warranted to explore this phenomenon.

We have previously reported that TSP1 induces cellular ROS (46, 49). In contrast, the endothelial cell response described here differs in its robust and sustained cumulative signal necessary for senescence induction. We provided evidence to show that TSP1 promoted specific human endothelial Nox1-derived ROS generation through CD47 but not SIRPα receptor engagement. These conclusions are drawn from (i) an observed increase in only Nox1 in HPAECs by Western blot, FACS, and mRNA analysis; (ii) effective inhibition and induction of ROS by blocking and stimulating CD47, respectively; and (iii) the ability of the Nox1-specific inhibitor NoxA1ds, but not of Nox2ds-tat (which is Nox2-specific), to suppress ROS (Fig. 4). The latter was corroborated using Nox1 siRNA (fig. S4). Moreover, TSP1 knockdown in aged mice elicited a decrease in Nox1 (but not in Nox2 or Nox4) at the mRNA and protein levels. Endothelial Nox1 (58, 70) exists in a constitutively active form or an inducible form (71). Because we discovered that human and murine aging, as well as TSP1 exposure, increased Nox1 abundance, we assert that the increase in ROS we observed is attributable to constitutive and chronic Nox1 activity. Thus, we submit that this chronic ROS generation, in turn, persistently drives DDR-related endothelial senescence (59).

Our findings that human Nox1 overexpression (Nox1OE) in HPAECs augmented the senescent phenotype are consistent with our observations of increased Nox1 abundance in aged human lung vasculature and after TSP1 challenge. Moreover, Nox1−/− deficiency lowered ROS production and p21cip abundance in middle-aged mice. In human cells, Nox1 inhibition reversed the ability of TSP1 to suppress proliferation and cell cycle progression and induce p53 nuclear localization and p21cip-positive cells. Further, overexpressing Nox1 resulted in increased ROS production, senescence, p21cip abundance, and Rb hypophosphorylation, consistent with a role of Nox1 in these processes (Fig. 5 and fig. S5). Together, these findings support the role of Nox1 in propagating endothelial ROS-induced senescence.

Finally, clinical and therapeutic implications of our findings were illustrated by age-dependent increases in two readouts of Nox-derived ROS production (O2•− and H2O2) in human lungs, along with robust increases in Nox1, p53, and p21cip (Fig. 6). Complementing these data further were cross sections of pulmonary artery illustrating a higher abundance of Nox1 and p21cip in the luminal endothelium. Finally, targeting Nox1 with its specific inhibitor NoxA1ds quelled senescence of human endothelial cells.

Members of the Nox family of isozymes, namely, Nox1, Nox2, and Nox4, have roles in proliferation and vessel remodeling (33, 72, 73). Thus, we did not expect Nox enzymes to play a role in aging-associated senescence. Finally, the specific transcriptional activators that increase Nox1 expression in the aging process will require exploration. The Nox1 promoter is reportedly responsive to various factors (74).

In summary, we found that a matricellular protein–induced, Nox1-derived ROS was responsible for p53-p21cip-Rb signaling and senescence, which were attenuated by Nox1 inhibition. Our findings linking TSP1/CD47, Nox1, and p53/p21/Rb to senescence in animal and human cells and during aging in human tissues are unique and previously unreported from both a mechanistic and a clinical standpoint. Finally, the exogenous delivery of Nox1 inhibitor(s) could offer therapeutic utility in the aging lung and other age-related pathologies.


Materials and reagents

Cytochrome c, superoxide dismutase (SOD), catalase, DPI, L-NAME, rotenone, phenylmethylsulfonyl fluoride (PMSF), β-Gal, and other reagents were purchased from Sigma-Aldrich. Amplex Red and propidium iodide were purchased from Invitrogen. Protease and phosphatase inhibitor cocktail tablets were purchased from Roche Diagnostics GmbH. Human TSP1 was purchased from Athens Research and Technology. Peptide 7N3 (RFYVVMYEGKK) was synthesized by Peptides International Inc. BrdU cell proliferation kit was from Cell Signaling Technology.

Human samples

The study was approved by the University of Pittsburgh Institutional Review Board, and written informed consent was obtained from all participating individuals. Lung and pulmonary artery (fifth branch) tissues from control non–pulmonary-diseased lung donors were provided by the PACCM (Division of Pulmonary, Allergy and Critical Care Medicine) Bio-Bank under protocols approved by the University of Pittsburgh Institutional Review Board. Tissues were harvested in optimal cutting temperature (OCT) medium, frozen, and sectioned (8 μm) for subsequent analysis (see below).


All animal studies were performed under a protocol approved by the Institutional Animal Care and Use Committee of the University of Pittsburgh. TSP1−/− and Nox1−/− mice (8 to 10 months old) on a C57BL/6 background, and age-matched wild-type C57BL/6 control mice were purchased from the Jackson Laboratory. Animals were sacrificed, and lungs were collected and either snap-frozen or embedded in OCT medium and frozen for further analysis.

HPAEC culture, TSP1 challenge, blocking antibody experiments, and NoxA1ds treatment

HPAECs (Lonza) were grown in EBM-2 (endothelial growth basal medium-2) containing EGM-2 (endothelial cell growth medium-2) BulletKit components (Lonza). Cells (passages 3 to 6) were seeded the day before the experimentation and synchronized in serum-reduced medium (1% fetal bovine serum) for 4 hours. Synchronized endothelial cells were treated with vehicle or TSP1 (2.2 nM) for 24 hours (or as indicated) and subjected to either homogenization in ice-cold disruption buffer (Hanks’ balanced salt solution containing 1.8 mM CaCl2, 0.8 mM MgCl2, and 0.1 mM PMSF), fixation in 2% paraformaldehyde/phosphate-buffered saline (PBS), or trypsinized for intact cell analysis. In some studies, blocking antibodies to CD47 (clone B6H12, Santa Cruz Biotechnology), SIRPα (clone C20, Santa Cruz Biotechnology), or CD36 (clone H-300, Santa Cruz Biotechnology) were added to the cell culture medium (1 mg/ml) for 3 min before TSP1 challenge. In addition, specific inhibition of the Nox1 enzyme was achieved using the NoxA1ds (10 μM) peptide (51) or its scrambled-ds peptide control (10 μM). In these experiments, cells were pretreated with peptides for 1 hour before TSP1 (2.2 nM) challenge.

siRNA gene silencing and Nox1 plasmid transfection

HPAECs were seeded at a density to achieve a 75 to 80% confluence overnight and were subjected to either p53 or Nox1 siRNA transfection (Santa Cruz Biotechnology) using the Lipofectamine 2000 transfection reagent (Invitrogen) according to the manufacturer’s protocol, as documented previously (51). To control for possible nonspecific effects of siRNA, control siRNA was used. Gene silencing was confirmed using immunoblotting, and the knockdown was expressed as a fold of siRNA controls. Nox1OE was achieved by transfecting cells with human Nox1 or an empty plasmid vector control, as published previously (75).

Cell proliferation assay

The in vitro proliferative capacity of HPAECs was analyzed using three independent assays. MTT proliferation assay was performed as described previously. Briefly, HPAECs were suspended in EGM-2–containing EBM-2 and plated on flat-bottomed 96-well plates at a density of 1 × 105 cells per well in triplicate. After overnight seeding (16 hours), cells were challenged with TSP1 (2.2 nM), and proliferation was assessed using MTT (Sigma-Aldrich) assay. Absorbance at 570 nm was read using a plate reader (BioTek Synergy 4 Hybrid Multi-Mode Microplate Reader), and the proliferation index was calculated relative to the absorbance value of the vehicle-treated controls. Trypan blue exclusion assay was performed as documented previously (76). Briefly, TSP1 (2.2 nM) was added to cultures of HPAECs for indicated periods after an overnight seeding and a 4-hour synchronization. Subsequently, cells were trypsinized, 10 μl of trypan blue (4% solution) was added to an equal volume of cell suspension, and cell numbers were counted using a hemocytometer. Cell numbers were normalized and expressed as a fold change over time from the start of the experiment (time, 0 hour). BrdU assay was performed as per the manufacturer’s instructions.

Cell cycle analysis

HPAECs were treated with TSP1 (2.2 nM; 24 hours), trypsinized, and analyzed for cell cycle phase analysis, as described previously (76). Briefly, after fixation in ice-cold 70% ethanol/PBS, cells were treated with ribonuclease A (0.2 mg/ml), and DNA content was stained with propidium iodide (50 μg/ml) at room temperature for 45 min. The number of cells in G0-G1, S, and G2-M phases and sub–G0-G1 apoptotic cells (77) was counted using a BD LSRFortessa flow cytometer and analyzed using the FlowJo software (version 10). A minimum of 10,000 events was recorded for each sample and are expressed as a percentage for each cell cycle phase.


Immunofluorescence microscopy was performed as described previously using endothelial cells cultured on 1% gelatin–coated chamber slides (78, 79). Primary antibodies were used at a 1:200 dilution in PBS with 0.1% bovine serum albumin (BSA) for 60 min at room temperature after a 15-min permeabilization of the cells in 0.25% Triton X-100 and 0.5% BSA/PBS. Species-specific fluorochrome-conjugated secondary antibodies (1:500) were applied to detect specific antigen localization, using fluorescein isothiocyanate (FITC) (green), Cy3 (red), and Cy5 (gray) as fluorochromes. DAPI (blue) was used to visualize the nuclei. Normal rabbit or goat immunoglobulin G (5 μg/ml) was used in the place of primary antibody as a negative control. Images were acquired on an Olympus FluoView-II inverted confocal microscope system and stored digitally for analysis. For immunofluorescence labeling of lung and pulmonary artery sections, 5-μm sections of OCT-embedded tissue were first washed with PBS and blocked in 10% BSA/PBS solution for 30 min at room temperature after permeabilization. To detect specific antigens, the staining procedure was performed as described above.

SA-β-Gal staining

HPAEC and lung senescence analysis was performed as detailed previously (35, 80). Briefly, samples were fixed in a 2% paraformaldehyde/PBS (pH 7.4) solution for 15 min at room temperature, washed in PBS twice, and then incubated with the freshly prepared SA-β-Gal staining solution [citric acid/sodium phosphate buffer (pH 6.0) containing X-Gal (1 mg/ml), 5 mM Fe(CN)63−, 5 mM Fe(CN)64−, 150 mM NaCl, and 2 mM MgCl2] for 24 hours in a humidified chamber placed in a non-CO2 incubator to maintain a buffered solution at pH 6.0. The following day, samples were washed in PBS twice, and images were captured at random using a light microscope (Leica Imaging Systems Ltd.). At least six images representing each condition were captured from each well and were blindly assessed for SA-β-Gal (blue)–positive cells.


Total cell and lung homogenates were generated as described previously (78). Soluble protein concentrations of the homogenates were determined using a plate-based Bradford assay kit (Thermo Fisher Scientific). Immunoblotting was conducted by loading 35 μg of protein per lane, as described previously (46). The images were captured digitally using a LI-COR biotechnology system, and the optical density of the protein bands was normalized to the loading control bands (quantified using ImageJ). Results were normalized to β-actin loading controls in each gel and expressed as a fold change from vehicle treatment.

FACS analysis of receptor and protein expression

CD47, SIRPα, and CD36 were assessed by FACS, as published previously (81). Briefly, intact HPAECs after trypsinization were incubated with primary antibodies, washed, and incubated with fluorescently labeled secondary antibodies with either FITC or Cy5. In some cases, notably when detecting Nox1, p21cip, or phospho-Rb by FACS, cellular permeabilization in 0.25% Triton X-100/PBS and blocking in 1% BSA/PBS for 30 min on ice were required. After antibody labeling, cells were counted using a BD LSRFortessa flow cytometer and analyzed using the FlowJo software (version 10). A minimum of 10,000 events were recorded for each sample.

ROS measurement

ROS production in endothelial cells was measured using four independent complementary assays. O2•− production by total cellular homogenates was measured by cytochrome c reduction, as described previously (46). O2•− production was initiated by the addition of 180 μM NADPH and was calculated from the initial linear rate of SOD (150 U/ml)–inhibitable cytochrome c reduction quantified at 550 nm and using an extinction coefficient of 21.1 mM−1 cm−1 (BioTek Synergy 4 Hybrid Multi-Mode Microplate Reader). Potential enzymatic sources of O2•− production were also investigated by using the following inhibitors: DPI (20 μM; flavoproteins), L-NAME (100 μM; NO synthases), rotenone (50 μM; mitochondrial complex I), or oxypurinol (100 μM; xanthine oxidase). Endothelial cell homogenate H2O2 production was measured using the Amplex Red (Invitrogen Inc.) assay, as described previously. Briefly, protein (50 μg/ml) was added to the wells on a 96-well plate containing the assay mixture [25 mM Hepes (pH 7.4) containing 0.12 M NaCl, 3 mM KCl, 1 mM MgCl2, 0.1 mM Amplex Red, and horseradish peroxidase (0.32 U/ml)]. The reaction was initiated by the addition of 36 μM NADPH, as published previously (46). Fluorescence was detected using the BioTek Synergy 4 Hybrid Multi-Mode Microplate Reader with a 530/25 excitation and a 590/35 emission filter. The reaction was monitored for 30 min at 25°C; the change in emission intensity was linear during this interval. To confirm the H2O2 signal, catalase (300 U/ml) was added in parallel wells, and the catalase-inhibitable rate of H2O2 production was quantified from an H2O2 standard curve. Lung ROS generation was investigated using the cytochrome c assay in total lung homogenates (see above), as well as using in situ DHE analysis of OCT-embedded mouse lung sections. Briefly, 5-μm-thick lung sections were incubated at room temperature with DHE (10 μM) for 30 min. Sections were examined by fluorescence microscopy (Leica Imaging Systems Ltd.), and fluorescence (490/580-nm excitation/emission wavelengths) intensity from 20 fields of lung sections was evaluated using the ImageJ software. In parallel sections, Tiron (cell-permeant O2•− scavenger; 10 mM) was added to determine the proportion of DHE fluorescence that was O2•−-dependent. Results obtained from fluorescence imaging are expressed as Tiron-inhibitable fluorescence intensity. Finally, to corroborate the results, ROS production was assessed by lucigenin-enhanced luminescence assay, as published previously (81).

Quantitative reverse transcription polymerase chain reaction

Total RNA was extracted from lung tissues using the RNeasy Plus kit (Qiagen) as per the manufacturer’s protocol. Total RNA was reverse-transcribed to complementary DNA by using SuperScript III (Invitrogen Inc.) following the manufacturer’s protocol. For qRT-PCR, commercially available primers for TSP1, Nox1, p53, and p21cip (Invitrogen Inc.) were used. All results were normalized to the housekeeping gene 18S, and relative quantification was obtained using the ΔCt (threshold cycle) method; relative expression was calculated as 2−ΔΔCt.


Data are means ± SEM of the results from at least three independent cell cultures, at least four to six animals per group, or six to eight human samples per group, as detailed in the figure legends. Comparisons were made by unpaired Student’s t test, Mann-Whitney test, linear regression, repeated-measures analysis, or one-way ANOVA. P < 0.05 was considered statistically significant.


Fig. S1. TSP1 is increased in aging human lung vasculature, and TSP1 exposure reduces endothelial cell proliferation.

Fig. S2. Age-dependent changes in senescence marker abundance in mice.

Fig. S3. TSP1 does not induce endothelial cell apoptosis.

Fig. S4. The TSP1-CD47 axis selectively regulates Nox1.

Fig. S5. Nox1 influences cell cycle progression and senescence.

Fig. S6. Age-dependent changes in Nox isoform abundance in human and mice lung samples.

Table S1. Characteristics of pulmonary disease–free human samples.

Table S2. Cause of death and existence of nonpulmonary diseases of the human samples.


Acknowledgments: We thank R. A. Bilonick for the constructive comments and C. Monzo for the assistance with the editing of this manuscript. Funding: This work was supported by NIH grants R01HL112914, R01HL079207, P01HL103455, and T32 GM008424 (to P.J.P.); AHA-15SDG24910003 (to I.A.G.); R01HL108954, 1R01HL112914-01A1, and 1R21EB017184-01A1 (to J.S.I.); R42-AA024003 and R01-CA162306 (to M.M.R.); 2R01HL098032, 1R01HL125886-01, P01HL103455, T32 HL110849, and T32 HL007563 (to M.T.G.); and 5 K23 HL112848-03 6 (to E.M.N.). This study was supported by the Institute for Transfusion Medicine and the Hemophilia Center of Western Pennsylvania. Author contributions: D.N.M. and P.J.P. conceived and designed the experiments. D.N.M., I.A.G., S.S., J.H.A., R.B.-M., H.E.K., S.A., and J.C.S. performed the experiments. D.N.M., I.A.G., S.S., E.C.-P., M.M.R., E.M.N., M.T.G., J.S.I., S.M.N., and P.J.P. analyzed and interpreted the data. D.N.M., P.J.P., E.C.-P., and S.S. drafted the manuscript. Competing interests: P.J.P. is named on a filed patent (US patent no. 9,187,528 B2) for NoxA1ds. All other authors declare that they have no competing interests.
View Abstract

Navigate This Article